Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence and machine learning to transform oncology drug development, announced a definitive agreement for a registered direct offering expected to generate approximately $4 million in gross proceeds. The company will issue 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at a purchase price of $1.09 per share. In a concurrent private placement, Lantern will also issue unregistered warrants to purchase up to 3,669,725 additional shares at an exercise price of $1.09 per share, potentially generating an additional $4 million in gross proceeds if fully exercised for cash. The offering is expected to close on or about Sept. 30, 2026, subject to customary closing conditions, with Rodman & Renshaw LLC acting as exclusive placement agent.
The net proceeds from the offering will be used for working capital and other general corporate purposes, according to the company. This capital injection is crucial for Lantern Pharma as it continues to develop its proprietary RADR AI and machine-learning platform, which integrates large-scale genomic and biological data to identify patients most likely to benefit from its therapies and guide biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.
For investors, the offering’s structure includes unregistered warrants that will become exercisable subject to stockholder approval and will expire five years following that approval. This could lead to potential dilution if the warrants are exercised, but it also provides the company with a pathway to additional capital without immediate dilution. The offering is a common financing strategy for clinical-stage biopharmaceutical companies that require funding to advance research and development without the revenue streams of commercial-stage companies. The news matters because it ensures Lantern Pharma can continue its operations and pursue its AI-driven approach to drug development, which could ultimately lead to more precise and effective cancer treatments.
The broader implications for the biopharmaceutical industry and investors are significant. Lantern Pharma’s use of AI to streamline drug development could reduce the time and cost associated with bringing new oncology therapies to market, a critical need given the high failure rates and expenses in oncology research. If successful, this approach could serve as a model for other companies, potentially accelerating the availability of new treatments for patients. For readers, this offering highlights the ongoing convergence of technology and healthcare, and the importance of innovative financing to support high-risk, high-reward research.
Investors seeking more information can view the full press release at https://ibn.fm/PCJbt. The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN. This announcement was distributed by InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides services including editorial syndication to 5,000+ outlets and social media distribution to millions of followers. For full terms of use and disclaimers, visit https://www.InvestorWire.com/Disclaimer.
